And then they shut down production in Spain!

Erin frowned. She realized all of this would make much more sense if Schiffer Hartwin also owned the patent for the enormously expensive oral drug Eloxium.

But they didn't. A French pharmaceutical company, Laboratoires Ancondor, produced Eloxium. Dr. Kender had told her one hundred and fifty thousand people in the U.S. were diagnosed with colon cancer each year. The income from Eloxium would end in more zeros than she could count.

But why would a German pharmaceutical cut way back on its Culovort production in its U.S. and Spanish facilities so a French pharmaceutical company could reap the profits?

Clearly, antitrust laws wouldn't allow them to profit directly. Was there some other way they were scratching each other's backs? Were there payoffs involved? Swiss bank accounts? Or were they so arrogant as to believe there would be no legal action if they violated the antitrust laws?

Erin smeared more crunchy peanut butter on her English muffin as she read about Serono, a Swiss biopharmaceutical company, that had tried to bring an AIDS drug to market "by concocting a dubious medical test," U.S. Attorney General Alberto R. Gonzales had alleged. The company "put its desire to sell the drug above the interests of patients." Serono had even offered doctors an all-expenses-paid trip to France to prescribe the drug.

Did she have to add doctors to the growing list of endlessly greedy professions?

She laid aside the stack of printouts that documented incredibly creative bad deeds by the pharmaceutical companies. What she needed now was to act.